{"product_id":"eurofins-five-forces-analysis","title":"Eurofins Scientific Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEurofins Scientific operates in a fragmented, high-growth life sciences testing market where strong supplier relationships, regulatory complexity, and scale-driven buyer expectations shape competitive intensity, while specialized capabilities and M\u0026amp;A activity raise barriers to entry and limit substitution risks; understanding these dynamics is critical for strategic positioning and valuation.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Eurofins Scientific’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Laboratory Equipment Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe high-end analytical instrument market is concentrated—Thermo Fisher Scientific and Agilent Technologies held roughly 40–50% global market share in lab instruments by 2024—giving suppliers pricing influence; Eurofins depends on them to run 200,000+ analytical methods across 900+ labs (2024), so vendor uptime and service matter. Eurofins’ scale provides some volume leverage and multi-year contracts, but unique instruments (e.g., high‑res mass specs) give suppliers moderate bargaining power on price and maintenance terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumables and Reagent Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins labs need constant high-quality reagents and specialist consumables; in 2024 Eurofins spent ~€350m on lab supplies, making vendors critical to operations.\u003c\/p\u003e\n\u003cp\u003eSupply-chain shocks in 2021–22 caused multi-week delays for 18% of shipments industry-wide, showing vendors can disrupt testing throughput and revenue.\u003c\/p\u003e\n\u003cp\u003eMany assays are reagent-specific, so switching suppliers often forces costly re-validation—typically 4–12 weeks and €10k–€100k per assay—raising supplier bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Scientific Personnel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe labor market for specialized scientists and lab technicians gives suppliers high bargaining power; Eurofins faces tight supply as vacancy rates for life-science roles hit ~8.2% in 2025 in EU lab hubs, up from 6.5% in 2020, pushing average senior scientist pay up ~18% since 2021.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized IT and Data Management Vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialized IT vendors wield strong supplier power: migrating Eurofins’ petabyte-scale lab datasets and retraining 50,000+ staff would cost hundreds of millions and months of downtime, so switching is rare.\u003c\/p\u003e\n\u003cp\u003eEurofins builds proprietary LIMS modules to reduce dependency, but still pays global cloud and cybersecurity providers (AWS, Microsoft, Google) likely \u0026gt;5% of IT spend for core infrastructure and risk coverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePetabyte data lock-in\u003c\/li\u003e\n\u003cli\u003eHigh retraining cost, long downtime\u003c\/li\u003e\n\u003cli\u003eProprietary software reduces but doesn’t remove dependence\u003c\/li\u003e\n\u003cli\u003eOngoing reliance on big cloud\/cyber vendors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal Estate and Facility Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOperating 900+ labs needs large, strategic real estate; in 2025 prime biotech hubs (Boston, London, Shanghai) report vacancy rates under 5%, giving landlords pricing power and tougher lease terms.\u003c\/p\u003e\n\u003cp\u003eEurofins mitigates supplier leverage by signing long-term leases and buying sites; in 2024 it invested ~EUR 200m in property capex and completed several acquisitions to secure capacity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e900+ labs worldwide\u003c\/li\u003e\n\u003cli\u003eBiotech hub vacancy \u0026lt;5% (2025)\u003c\/li\u003e\n\u003cli\u003eEUR 200m property capex (2024)\u003c\/li\u003e\n\u003cli\u003eLong-term leases and acquisitions reduce risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuppliers Hold Strong Leverage: Instruments, Reagents \u0026amp; Real Estate Drive High Switching Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers exert moderate-to-high bargaining power: key instrument vendors (Thermo Fisher, Agilent ~40–50% share by 2024) and reagent suppliers (Eurofins spent ~€350m on lab supplies in 2024) create switching costs (4–12 weeks, €10k–€100k per assay). IT and data lock-in raise costs; property pressures in biotech hubs (vacancy \u0026lt;5% in 2025) add landlord leverage despite EUR 200m capex in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab supply spend 2024\u003c\/td\u003e\n\u003ctd\u003e€350m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstrument market share\u003c\/td\u003e\n\u003ctd\u003eThermo\/Agilent 40–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssay re-validation\u003c\/td\u003e\n\u003ctd\u003e4–12 weeks, €10k–€100k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech vacancy 2025\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProperty capex 2024\u003c\/td\u003e\n\u003ctd\u003e€200m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Eurofins Scientific, this Porter's Five Forces overview uncovers competitive pressures, supplier and buyer influence, entry barriers, substitutes, and emerging threats that shape pricing power and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear, one-sheet Porter's Five Forces for Eurofins Scientific—instantly highlights competitive pain points and strategic levers for faster, board-ready decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Pharmaceutical and Biotech Corporations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge pharma and biotech firms are high-volume clients for Eurofins, often negotiating double-digit price concessions and bespoke SLAs; in 2024, the top 20 pharma firms accounted for an estimated 30–40% of global outsourced testing spend, so they consolidate with few global labs to increase leverage. Still, drug-safety and regulatory risk mean these customers pay premiums for proven technical expertise and ISO\/GLP-compliant capacity, reducing pure price pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Food and Beverage Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal food and beverage manufacturers demand rigorous contaminant, authenticity, and nutrition testing to meet regulators; Eurofins handled ~55% of its 2024 testing revenue from food-related services, showing deep exposure to this segment.\u003c\/p\u003e\n\u003cp\u003eThese large clients can negotiate lower per-test fees due to volume, but integrations for supply-chain transparency tie them to Eurofins’ platform, raising switching costs.\u003c\/p\u003e\n\u003cp\u003eGiven recall costs—average global food recall cost ~USD 10–30m—many manufacturers pay premiums for Eurofins’ brand trust and accredited labs, reducing buyer price sensitivity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment and public health agencies contract Eurofins for environmental monitoring, forensic testing, and mass diagnostics—contracts that can total tens to hundreds of millions; e.g., Eurofins reported €5.6bn revenue in 2024, with public-sector programs a material share.\u003c\/p\u003e\n\u003cp\u003eThese awards use competitive tenders that compress margins; public bids often demand low unit pricing and strict SLA penalties, reducing EBITDA on such work.\u003c\/p\u003e\n\u003cp\u003eAgencies wield high power by setting testing standards and regulations; compliance costs and accreditation (ISO 17025) are mandatory for market access, raising barriers for smaller labs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching Costs and Technical Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFor many industrial clients, switching Eurofins for another testing provider causes logistical hurdles and product-launch delays, raising effective switching costs—Eurofins served ~60,000 clients in 2024, so network effects matter.\u003c\/p\u003e\n\u003cp\u003eData-system integration (LIMS and reporting) creates a sticky relationship that lowers immediate customer bargaining power; integrated clients report ~20–30% faster issue resolution versus ad hoc labs.\u003c\/p\u003e\n\u003cp\u003eClients who validated QC using Eurofins’ methods face retraining, revalidation and regulatory review costs, making competitor moves costly and slow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~60,000 clients (2024) increases lock-in\u003c\/li\u003e\n\u003cli\u003e20–30% faster resolution with integrated systems\u003c\/li\u003e\n\u003cli\u003eRevalidation\/regulatory costs deter switching\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFragmentation of Small and Medium Enterprises\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa significant portion of eurofins clients are smes that lack scale to demand steep discounts in roughly revenue came from customers generating under testing spend limiting their bargaining leverage.\u003e\n\u003cpsmes prioritize test breadth and fast turnaround to meet local regulatory deadlines so eurofins wide portfolio methods across labs worldwide in retains them.\u003e\n\u003cpeurofins holds high power over smes because local labs cannot match its specialized tests networked capacity or day turnaround guarantees for many assays.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~60% revenue from SME accounts (2024)\u003c\/li\u003e\n\u003cli\u003e200,000+ test methods; 800+ labs (2024)\u003c\/li\u003e\n\u003cli\u003eTypical SME priority: breadth + speed\u003c\/li\u003e\n\u003cli\u003eLocal labs lack scale\/specialized assays\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/peurofins\u003e\u003c\/psmes\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMixed customer power: tenders squeeze pharma, SMEs pay premiums—Eurofins’ scale boosts stickiness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomers exert mixed power: large pharma\/public tenders push prices via volume and tenders (top 20 pharma ~30–40% outsourced spend; public bids cut margins), while food clients and SMEs pay premiums for accredited, fast, integrated services (Eurofins: €5.6bn revenue, ~60,000 clients, 60% SME revenue, 800+ labs, 200,000+ methods in 2024), raising switching costs and limiting pure price pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€5.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClients\u003c\/td\u003e\n\u003ctd\u003e~60,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSME % rev\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabs \/ methods\u003c\/td\u003e\n\u003ctd\u003e800+ \/ 200,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eEurofins Scientific Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Eurofins Scientific Porter’s Five Forces analysis you’ll receive immediately after purchase—no mockups or placeholders; the full, professionally formatted document is ready for instant download and use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747541266809,"sku":"eurofins-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/eurofins-five-forces-analysis.png?v=1772199654","url":"https:\/\/matrixbcg.com\/products\/eurofins-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}